Antigen News and Research

RSS

Shells of plant virus trigger immune system to wipe out tumors, provide protection against metastases

The shells of a common plant virus, inhaled into a lung tumor or injected into ovarian, colon or breast tumors, not only triggered the immune system in mice to wipe out the tumors, but provided systemic protection against metastases, researchers from Case Western Reserve University and Dartmouth University report.

23 Dec 2015

Univercells awarded grant to reduce cost of vaccine manufacturing in the Walloon region

Univercells SA, a company that designs single-use cost-efficient bioprocess solutions for the next generation of biomanufacturing, today announces that it has received a grant from the Walloon region.

21 Dec 2015

Adaptimmune begins Phase I/II study of affinity enhanced T-cell therapy targeting MAGE-A10 in NSCLC patients

Adaptimmune Therapeutics plc, a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it has initiated a Phase I/II study of its affinity enhanced T-cell therapy targeting the MAGE-A10 cancer antigen in patients with locally advanced or metastatic (Stage IIIb or IV) non-small cell lung cancer (NSCLC), the most prevalent type of lung cancer representing approximately 85 percent of lung cancers.

21 Dec 2015

UCL Cancer Institute win $200,000 CytoFLEX Flow Cytometer from Beckman Coulter

An internationally renowned gene therapy research team has won a $200,000 CytoFLEX Flow Cytometer from Beckman Coulter Life Sciences.

From Beckman Coulter Life Sciences - Flow Cytometry 18 Dec 2015

CRCHUM researchers find mechanism responsible for rejection of organ transplants

A new cellular structure responsible for previously unexplained rejection of organ transplants has been identified by researchers at the University of Montreal Hospital Research Centre.

17 Dec 2015

Simple diagnostic test can help fight deadly sleeping sickness

Scientists have developed a quick and simple diagnosis method, similar to a dipstick pregnancy test, to fight a deadly sleeping sickness.

16 Dec 2015

TSRI scientists track how HIV-fighting antibodies develop over time

In a new study, a team led by scientists at The Scripps Research Institute tracked how a family of these HIV-fighting antibodies develops over time. The research shows how a future vaccine might trigger the immune system to produce these antibodies more effectively.

16 Dec 2015

Exposure to farm animals, pets in early childhood modifies allergy-related immunological mechanisms

Exposure to farm animals in early childhood modifies the key allergy-related immunological mechanisms, shows a recent study from the University of Eastern Finland. The study provides new insight into the role of dendritic cells and cytokine production in particular.

15 Dec 2015

Study: Brain cell death may trigger multiple sclerosis

Multiple sclerosis (MS) may be triggered by the death of brain cells that make myelin, the insulation around nerve fibers, according to research on a novel mouse model developed by scientists from the University of Chicago and Northwestern Medicine. The death of these cells initiates an autoimmune response against myelin, the main characteristic of the disease, which leads to MS-like symptoms in mice.

14 Dec 2015

ImmunoCellular partners with CBTC for ICT-107 phase 3 registrational trial in patients with glioblastoma

ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with a major Canadian cancer cooperative group, The Canadian Brain Tumour Consortium, for the phase 3 registrational trial of its cancer immunotherapy ICT-107 in patients with newly diagnosed glioblastoma.

14 Dec 2015

Repeating abnormal PSA tests can reduce unnecessary biopsies

For more than 20 years, the prostate-specific antigen (PSA) test has been used to help screen for prostate cancer, but in recent years, some task forces have called for this blood test to be abandoned because it leads to many unnecessary biopsies.

11 Dec 2015

BioAtla, Pfizer sign license and option agreement for new class of antibody therapeutics

BioAtla LLC, a biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into a license and option agreement with Pfizer Inc. to advance the development and commercialization of a new class of antibody therapeutics based on BioAtla's CAB platform and utilizing Pfizer's proprietary antibody drug conjugate (ADC) payloads.

8 Dec 2015

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

New research adds to a growing body of evidence that gene therapy, an experimental technique that involves correcting or replacing a person's mutated or malfunctioning genes, may improve health outcomes for patients with inherited bleeding and immune disorders as well as some forms of blood cancer.

7 Dec 2015

HBsAg may persist in chronic HBV patients beyond seroclearance

The use of a highly sensitive assay for the detection of hepatitis B surface antigen suggests that HBsAg negativity as evaluated by the conventional test may not be indicative of seroclearance in patients with chronic hepatitis B virus infection.

3 Dec 2015

Combining medications may increase HBsAg loss in HBV patients

Combining tenofovir disoproxil fumarate with pegylated interferon alfa-2a may improve the chances of hepatitis B surface antigen loss in patients with hepatitis B virus infection, suggests a randomised trial.

3 Dec 2015

Heptares announces strategic drug discovery collaboration with Pfizer

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, announces that it has entered into a strategic drug discovery collaboration with Pfizer Inc. to research and develop potential new medicines directed at up to 10 G protein-coupled receptor (GPCR) targets across multiple therapeutic areas.

30 Nov 2015

Personalised peptide vaccination promising in bladder cancer

Metastatic bladder cancer patients who have progressed on first-line platinum-based chemotherapy could derive survival benefits from personalised peptide vaccination, according to phase II trial results.

27 Nov 2015

Clinical study shows new Ebola vaccine stimulates strong immune responses in adults

A clinical trial of a new Ebola vaccine (ChAd3-EBO-Z) that resulted from an unprecedented global consortium assembled at the behest of the World Health Organization has found that it is well tolerated and stimulates strong immune responses in adults in Mali, West Africa and in the US, according to a study published in the latest issue of the journal Lancet Infectious Disease.

19 Nov 2015

Novel immunotherapeutic approach could improve outcomes for patients with advanced bladder cancer

Noguchi explained that immunotherapy has emerged recently as a viable and attractive strategy for the treatment of advanced cancer.

18 Nov 2015

Two studies find decline in PSA screening and prostate cancer incidence

Two studies in the November 17 issue of JAMA examine the change in prostate-specific antigen (PSA) screening and prostate cancer incidence before and after the 2012 U.S. Preventive Services Task Force (USPSTF) screening recommendations.